Regencell Bioscience Financial Ratios
NASDAQ: RGCHealth Care Medicinal Chemicals and Botanical Products USD
7.35-0.28 (-3.67%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Regencell Bioscience ratio analysis
Return on equity reached -87.7%, meaning Regencell Bioscience generated -0.88 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Regencell Bioscience financial ratios (annual)
| Ratio | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Price / book | 236.01 | 2,339.02 | 5.32 | 24.92 | 0.71 | — | — | — |
| Return on equity (ROE) | -87.7% | -73.7% | -52.3% | -48.8% | -43.6% | — | — | — |
| Return on assets (ROA) | -79.4% | -62.3% | -51.0% | -46.5% | -41.3% | -395.9% | -158.0% | — |
| Current ratio | 10.77 | 7.39 | 41.92 | 19.15 | 28.46 | 0.02 | 0.12 | — |